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Background: The human progesterone receptor (hPR) belongs to the steroid receptor family. 
It may be found as monomers (A and B) and or as a dimer (AB). hPR is regarded as the 
prognostic biomarker for breast cancer. In a cellular dimer system, AB is the dominant species 
in most cases. However, when a cell coexpresses all three isoforms of hPR, the complexity of 
the action of this receptor increases. For example, hPR A suppresses the activity of hPR B, and 
the ratio of hPR A to hPR B may determine the physiology of a breast tumor. Also, persistent 
exposure of hPRs to nonendogenous ligands is a common risk factor for breast cancer. Hence 
we aimed to study progesterone and some nonendogenous ligand interactions with hPRs and 
their molecular docking.
Methods and results: A pool of steroid derivatives, namely, progesterone, cholesterol, 
testosterone, testolectone, estradiol, estrone, norethindrone, exemestane, and norgestrel, was used 
for this in silico study. Dockings were performed on AutoDock 4.2. We found that estrogens, 
including estradiol and estrone, had a higher affinity for hPR A and B monomers in comparison 
with the dimer, hPR AB, and that of the endogenous progesterone ligand. hPR A had a higher 
affinity to all the docked ligands than hPR B.
Conclusion: This study suggests that the exposure of estrogens to hPR A as well as hPR B, 
and more particularly to hPR A alone, is a risk factor for breast cancer.
Keywords: human progesterone receptor, breast cancer, steroid derivatives, estrogens,   molecular 
docking
Introduction
The human progesterone receptor (hPR), like other members of the steroid receptor 
family of proteins, is a ligand-induced transcription factor which mediates the effects 
of progesterone.1–3 Progesterone is well known for its critical role in regulation of the 
normal physiology of the ovary, uterus, mammary gland, as well as brain development 
during childhood. Progesterone also plays an important role in the maintenance of the 
cardiovascular, central nervous, and skeletal systems.4–7 The importance of the hPR 
can therefore be understood from its extensive involvement in human physiological 
processes.
hPR is comprised of specific functional domains, including the central DNA-binding 
domain and a carboxyl-terminal ligand-binding domain. The central DNA-binding and 
ligand-binding domains are the sites of hPR activity. In addition to these domains, hPR 
have many elements with activator and inhibitory functions enhancing and repressing 
the transcriptional activation of hPR by their interaction with different transcriptional 
coregulators.3,8–12 Cytoplasmic hPR have been found as multiprotein chaperone 
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complexes which facilitate their inactive conformation, 
whereby a ligand can bind with hPR.13,14
Two distinct isoforms (hPR A and hPR B) of hPR have 
been reported previously, and differ by an additional amino 
acid at position 164 in hPR B. These differences arise as a 
result of either alternate initiation of translation by the same 
mRNA or by transcription from alternate promoters within 
the same gene.15
Our understanding of the mechanisms underlying the 
different activities of these two isoforms of human hPR is 
limited. However, structural and functional studies indicate 
that the hPR B isoform contains an additional domain, AF3, 
that accounts for the transcriptional activity of hPR B by 
suppressing the activity of an inhibitory domain contained 
within the sequences common to hPR A and hPR B.11,16,17 
The evidence suggests that the two isoforms acquire different 
conformations within the cell, and hence interact with distinct 
coregulators, ie, the coregulators of hPR A are different from 
those of hPR B.18–20
Much of our knowledge regarding the structure and 
function of hPR A and hPR B comes from models of 
single hPR isoform expression and models where the hPR 
homodimer is the dominant molecular species. However, cell 
types which coexpress the hPR isoforms may possibly have 
all three kinds of molecules, ie, hPR A, hPR B, and hPR AB, 
which increases the complexity of the action of hPR.
hPR is a ligand-activated receptor, and its activation/
deactivation is associated with the pathogenesis of many 
diseases, including breast cancer.21,22 Hence, the specificity of 
hPR with regard to interaction with its ligand (progesterone) 
is an important area of research. It has been reported that 
prolonged exposure to certain nonendogenous ligands, 
particularly estrogens (which are steroid derivatives) is the 
strongest risk factor for breast cancer.23,24 In the absence of 
progesterone, the hPR A:hPR B ratio influences the biology 
of estrogen receptor-positive tumors and their response to 
treatment, and hPR A isoforms are functionally dominant in 
progesterone-deficient states. This explains why PR A-rich 
tumors are particularly aggressive.25 We hypothesized that 
hPR A, hPR B, and hPR AB have different affinities for dif-
ferent ligands, based on conditions such as the availability of 
progesterone and the concentration of hPR monomers and 
dimers, which may be a possible cause for the development of 
breast cancer. The aim of our study was to test this hypothesis 
and find the affinities of the different steroid derivatives for 
hPRs. Hence, other steroids that can trigger the develop-
ment of breast cancer by forming a ligand receptor complex 
with hPR can be predicted. A battery of steroid derivatives, 
namely, progesterone (DB00396), cholesterol (DB04540), 
testosterone (DB00624), testolectone (DB00894), estradiol 
(DB00783), estrone (DB00655), norethindrone (DB00717), 
exemestane (DB00990), and norgestrel (DB00506), was used 
for this in silico study (Figure 1).
Methods and materials
software, data sources, and experiments
All the software used in this study is freely available for 
academic use. Table 1 provides the source of the data, and 
Table 2 lists the software and online servers used. The Protein 
Data Bank (www.rcsb.org) is a World Wide Web repository 
where data are processed and distributed in the form of 
three-dimensional biological macromolecular structures.26 
The Protein Data Bank now has more than 20,000 structures 
determined by x-ray diffraction. Protein structures can be 
accessed and downloaded using keywords or the Protein 
Data Bank alphanumeric file name.
The Drug Bank (http://redpoll.pharmacy.ualberta.ca/
drugbank/) database is a unique bioinformatics and chemin-
formatics resource that combines detailed drug (ie, chemical, 
pharmacological, pharmaceutical) data with comprehensive 
drug target information (ie, sequence, structure, pathway).27 
The database contains nearly 4300 drug entries, including 
more than 1000 small molecule drugs approved by the US 
Food and Drug Administration (FDA), 113 FDA-approved 
biotechnologic (protein/peptide) drugs, 62 nutraceuticals, 
and more than 3000 experimental drugs. Additionally, more 
than 6000 protein (ie, drug target) sequences are linked to 
these drug entries. Each drug card entry contains more than 
80 data fields, with half of the information concerning drug 
and chemical data and the other half concerning drug target 
or protein data.
PyMOL is a Python-based visualization program 
(version1.1r1; Delano Scientific 2006, www.pymol.org).28 
PyMOL was used to obtain graphical representations of 
proteins in the Protein Data Bank and the amino acid residues 
are in contact with the ligand. PyMOL tools can measure 
distances as well as identify different amino acid residues 
of receptors that interact with the ligands. Docking results 
were also analyzed by PyMOL.
AutoDock 4.2 docking software (Scripps Research 
Institute, www.scripps.edu) and AutoDockTools was used 
to perform the docking experiments.29–31 AutoDockTools is 
an accessory program that allows the user to interact with 
AutoDock from a graphic user interface. AutoDock is a 
suite of automated docking tools designed to predict how 
small molecules/ligands bind to a receptor/protein of known Advances and Applications in Bioinformatics and Chemistry 2011:4 submit your manuscript | www.dovepress.com
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three-dimensional structure. AutoDock consists of three 
separate programs, ie, AutoDock, which docks the ligand 
to a set of grids describing the target protein, AutoGrid, 
which precalculates these grids, and AutoTors, which sets 
up bonds which will be treated as rotatable within the ligand. 
We calculated the binding energy of the different ligands 
for hPR A, hPR B, and hPR AB, and the molecular docking 
process was performed according to the method described 
by Mukharjee and Majumder.32 The details of the procedure 
are as follows.
Preparing hPRs and ligand files  
for AutoDock
The Protein Data Bank files downloaded from the World 
Wide Web repository are often not perfect for docking 
studies because of missing hydrogen atoms, presence of 
multiple molecules, added waters, and related problems. 
Using the AutoDockTools graphic user interface, the files 
were prepared as follows.
For the hPRs file, all heteroatoms in the Protein Data 
Bank files were removed. Three separate Protein Data Bank 
files were then prepared for hPR A, hPR B, and hPR AB, and 
saved with an extension of .pdb. All three Protein Data Bank 
files were first read in AutoDockTools, any added waters 
removed, and polar hydrogens added. AutoDockTools was 
then used to check if the molecule had charges and, if not, 
AutoDockTools determined whether the molecule was a 
peptide (ie, whether all of the names of its residues appeared 
Progesterone
Testolactone
Norethindrone
Cholesterol
Estradiol
Exemestane
Testosterone
Estrone
Norgestrel
HO
OH
CH3
O
O
CH3
CH3
CH2
HO
O
CH3
CH
O
HO
CH3
O
OH
CH3
CH3
HO
CH3
CH3
CH3
H3C
H3C
O
HO CH H3C
O
O
CH3
CH3
CH3
O
O
O
H3C
H3C
Figure 1 structure of ligands (as retrieved from Drug Bank) used for docking study.
Table 1 sources of data used in this study
Protein or drug data Source
Human progesterone receptor  PDB iD 1A28
Progesterone DB00396
Cholesterol DB04540
Testosterone DB00624 
Testolectone DB00894
estradiol DB00783
estrone DB00655 
norethindrone DB00717 
exemestane DB00990
norgestrel DB00506
Abbreviations: PDB, Protein Data Bank; DB, Drug Bank.Advances and Applications in Bioinformatics and Chemistry 2011:4 submit your manuscript | www.dovepress.com
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in the standard set of 20 commonly occurring amino acids). 
If the molecule was found to be a peptide, Kollman charges 
were added, otherwise Gasteiger charges were added. Finally, 
solvation parameters were added, and the files were saved 
with .pdbqs extension (where q and s represent charge and 
solvation, respectively).
Ligand files
Protein Data Bank files of ligands obtained from the Drug 
Bank, were read in AutoDockTools, modified as necessary, and 
saved using .pdbqs extension. AutoDockTools was then used 
for automatic calculation of the best root, ie, the fixed portion 
of the ligand from which rotatable branches sprout. We also 
determined the rotatable bonds in the ligand, making all amide 
bonds nonrotatable, and set the number of active torsions to the 
least number of atoms. The ligand files were then saved with 
ligand.out.pdbq extension (q representing charge).
Grid parameter files
For the calculation of interaction energy, parameters were 
set to create a grid (ie, a three-dimensional box) capable of 
enclosing hPRs molecules. The grid volume was large enough 
to allow the ligand to rotate freely, even with its most fully 
extended conformation. Grid parameters were stored in a 
grid parameter file using molecule.gpf extension.
Autogrid4 program
The AutoGrid4 program was run, creating a map for every 
type of atom in the ligand. For example, a molecule having 
carbon, nitrogen, oxygen, and hydrogen maps was created 
as a molecule.C.map, molecule.N.map, molecule.O.map, 
and molecule.H.map. These grid maps were saved in ASCII 
format for readability by AutoDock. AutoGrid also generates 
a corresponding output of the macromolecular file with the 
extension molecule.glg.
Docking parameter file
The docking parameter file and other properties defined for 
the ligand was created. A docking parameter file instructs 
AutoDock on which ligand to move and the map files to use. 
AutoDock’s search methods include the Monte Carlo simulated 
annealing method, the genetic algorithm, local search, and the 
hybrid genetic algorithm with local search (GALS). The GALS 
is also considered as the Lamarckian genetic algorithm because 
the offsprings are allowed to inherit the local search adaptations 
of their parents. GALS was the chosen algorithm for hPR and 
ligand interaction analysis.
AutoDock program
Finally, the AutoDock program was run from the AutoDock 
graphic user interface, and the docked ligand files 
(.dlg extension) were used for this study. The .dlg files were 
read in Autodock as well as in PyMOL to calculate the 
binding energies in the docked ligand-protein complexes.
Results
Rigorous docking experiments were done to assess the 
cross-reactivity of various steroid derivatives (ligands) with 
hPR monomers and dimers. The ligands, receptors, and their 
corresponding docking results are listed in Table 3, and 
receptor-ligand interactions demonstrated in Figures 2, 3, 
and 4. In these docking experiments, all selected ligands 
were able to bind with hPR A. Estradiol showed the high-
est binding affinity (∆G kcal/mol) at −3.68e+06, followed 
by estrone, progesterone, and cholesterol (3.38e+06, 
−3.54e+06, and −2.19e+06 kcal/mol, respectively). 
Testosterone, testolactone, norethindrone, exemestane, and 
norgestrel exhibited binding affinities in the range of −8.73 
to −7.14 kcal/mol. Ligand interactions with hPR B showed 
lower binding affinity than with hPR A. A similar pattern of 
binding affinity was found for ligands with hPR B, except 
for progesterone and cholesterol. Estradiol had the highest 
binding affinity at −3.64e+6 kcal/mol followed by estrone, 
cholesterol, and progesterone (3.19e+6, −2.53e+6, and 
2.05e+6 kcal/mol, respectively). Testosterone, testolactone, 
norethindrone, exemestane, and norgestrel exhibited binding 
affinities in the range of −5.86 to −4.75 kcal/mol. All the 
ligand interactions with hPR homodimer (AB) had similar 
binding affinity, except for cholesterol, which had a   binding 
affinity of −1.86e+6 kcal/mol, which was the highest   binding 
affinity among all the ligand interactions with hPR AB. 
  Progesterone had a binding affinity of −10.82 kcal/mol, and 
the remainder of the ligand binding affinities were in the 
range of −9.82 to −8.50 kcal/mol.
Using this molecular modeling study, we found that 
the estrogens, estradiol and estrone, had higher affinity 
Table 2 software and online servers and corresponding UrLs
Protein Data Bank file and FASTA format of hPR rCsB server online http://www.pdb.org/pdb/explore/explore.do?structureid=1A28
PyMOL image PyMOL 1.1r1 http://download.cnet.com/PyMOL/3000-2054_4-10914845.html
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for the hPR monomers A and B. Therefore, we undertook 
binding site analyses for hPR A, B, and AB, for estradiol 
and estrone. Table 4 summarizes the amino acid residues 
involved in the binding of estradiol and estrone with hPR A, 
hPR B, and AB. Only the HIS 93 residue of hPR A created 
a single hydrogen bond (H-bond) with estradiol and estrone 
(bond length 2.0 and 2.3 Å, respectively). In the case of 
hPR B, estradiol created two H-bonds, one with TRP 78 
(2.2 Å) and the other with ARG 89 (2.0 Å), whereas estrone 
made three H-bonds, two with GLN 48 (2.2 and 2.2 Å) and 
one with ARG 89 (2.1 Å). Interestingly, hPR AB was not 
involved in the formation of any H-bond with estrone and 
only ASP 205 of hPR AB made a single H-bond with estra-
diol (1.7 Å). The rest of the amino acid residues listed in 
Table 4 were involved in hydrophobic interactions through 
their side chains.
Discussion
Specificity in biomolecular interactions is determined mainly 
by noncovalent forces like Coulombic electrostatic forces, 
hydrogen bonds, London’s dispersive forces, and van der 
Waals forces. In addition, the structure of biomolecules is a 
function of forces among the constituent structural elements, 
as well as environmental forces. Binding affinity is inversely 
proportional to free Gibbs energy. To find the specificity of 
hPR for different steroid derivatives, monomers and dimers 
of hPR were studied separately because it had been found 
in vivo that there is a difference in the binding pattern of 
Progesterone
Testolactone
Norethindrone
Cholesterol
Estradiol
Exemestane
Testosterone
Estrone
Norgestrel
A  BC
F E D
GH I
Figure 2 Progesterone (A), cholesterol (B), testosterone (C), testolactone (D), 
estradiol (E), estrone (F), norethindrone (G), exemestane (H), and norgestrel (I) 
docked onto the human progesterone receptor A (hPr A, green) in its lowest 
energy-docked conformation. Ligand molecules are shown in red.
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Figure 3 Progesterone (A), cholesterol (B), testosterone (C), testolactone (D), 
estradiol (E), estrone (F), norethindrone (G), exemestane (H), and norgestrel (I) 
docked onto the human progesterone receptor A (hPr B green) in its lowest 
energy-docked conformation. Ligand molecules are shown in red.
Table 3 Docking results of steroid derivative (ligand) molecules at human progesterone receptor chains (A, B, and AB, blind docking)
Steroid derivative  
(ligands)
hPR A hPR B hPR AB
∆G (kcal/mol) Figure number ∆G (kcal/mol) Figure number ∆G (kcal/mol) Figure number
Progesterone −3.54e+06 2A −2.05e+06 3A −10.82 4A
Cholesterol −2.19e+06 2B −2.53e+06 3B −1.86e+06 4B
Testosterone  −7.14 2C −4.75 3C −9.39 4C
Testolactone  −7.99 2D −5.40 3D −9.33 4D
estradiol  −3.68e+06 2e −3.64e+06 3e −8.50 4e
estrone  −3.38e+06 2F −3.19e+06 3F −9.03 4F
norethindrone  −8.73 2g −5.86 3g −9.52 4g
exemestane  −8.03 2H −5.41 3H −9.82 4H
norgestrel  −8.30 2i −5.48 3i −9.55 4i
Abbreviation: hPr, human progesterone receptor.Advances and Applications in Bioinformatics and Chemistry 2011:4 submit your manuscript | www.dovepress.com
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ligands to hPR A and B. They adopt distinct conformations in 
cells, as well as having different signaling responses.18–20,33–35 
Earlier studies of elephant and hamster uterine progesterone 
receptors reported that there are many natural and synthetic 
steroid derivatives which are nonendogenous ligands and have 
higher relative binding affinity with progesterone receptors 
as compared with progesterone.36,37 Similarly, progesterone 
is the endogenous ligand for hPR, but in this in silico study, 
where there was one-to-one correspondence between hPRs and 
ligands, as well as their flexible docking, we found that estradiol 
has more affinity with hPR A than progesterone, and estrone 
had less affinity with hPR A as compared with progesterone, 
Progesterone
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Figure 4 Progesterone (A), cholesterol (B), testosterone (C), testolactone (D), estradiol (E), estrone (F), norethindrone (G), exemestane (H), and norgestrel (I) docked 
onto the human progesterone receptor A (hPr AB green) in its lowest energy-docked conformation. Ligand molecules are shown in red.
Table 4 Amino acid residues involved in binding of estradiol and estrone with human progesterone receptors A, B, and AB
Human progesterone receptors hPR-A hPR-A hPR-B hPR-B hPR-AB hPR-AB
Estrogens Esterone Estradiol Esterone Estradiol Esterone  Estradiol
Amino acids constituting gLU A 18 gLU A 18 LeU B 38 LeU B 38 LYs B 155 His A 204
the binding sites  PrO A 19 PrO A 19 LeU B 41 Asn B 42 His B 204 AsP A 205*
of estrogens VAL A 21 AsP A 20 Asn B 42 LeU B 44 iLe B 208 LYs A 208
iLe A 22 VAL A 21 LeU B 44 gLn B 48 PrO B 243 LeU A 244
gLn A 48 iLe A 22 gLn B 48** TrP B 78* VAL B 248 LYs B208
ser A 51 gLn A 48 TrP B 78 MeT B 79 LYs B 249 iLU B 243
VAL A 52 ser A 51 MeT B 79 MeT B 82 LeU B 250 LeU B 244
LeU A 81 VAL A 52 MeT B 82 VAL B 83 MeT B 247
MeT A 82 LeU A 81 VAL B 83 LeU B 86
TrP A 88 MeT A 82 LeU B 88 Arg B 89*
Arg A 89 LeU A 86 Arg B 89* PHe B 101
His A 93* TrP A 88 PHe B 101 LeU B 104
PHe A 141 Arg A 89 LeU B 120 PHe B 117
LYs A 145 His A 93* MeT B 124 LeU B 120
PHe A 141 LeU B 210 MeT B 124
LYs A 145 TUr B 213 LeU B 210
CYs B 214 TYr B 213
PHe B 228 CYs B 214
MeT B 232 THr B 217
MeT B 232
Notes: *Amino acids in the binding sites involved in the formation of a single H-bond with estrogens; **Amino acids in the binding sites involved in the formation of double 
H-bonds with estrogens.
Abbreviation: hPr, human progesterone receptor.Advances and Applications in Bioinformatics and Chemistry 2011:4 submit your manuscript | www.dovepress.com
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whereas cholesterol has a higher Gibbs energy value compared 
with progesterone. In the case of hPR B, estrone, estradiol, and 
cholesterol molecules had higher affinity with hPR B than did 
progesterone. In general, the binding energy for the ligands 
with hPR A was considerably higher than that of hPR B. This 
supports the view that, in the presence of hPR A and hPR B 
monomers in a cellular system, hPR A can exert an inhibitory 
effect on the transactivator behavior of hPR B.16,17 Our finding is 
also in agreement with earlier studies showing that hPR A-rich 
tumors are more aggressive.25 The higher binding affinity of 
ligands like estradiol and estrone for hPR A than for hPR B is 
supported by the previous study which showed that cumulative 
exposure of estradiols to hPR is the most common risk factor 
for the development of breast cancer.
Prolonged lifetime exposure to estrogens, especially 
estrone and estradiol, has long been linked to the promotion 
and progression of breast cancer because of their physi-
ological action on the mammary gland.23,24 Another in vitro 
study also reports significantly increased stimulation of the 
progesterone receptor by estrone,38 although there is a lot 
of evidence suggesting that binding of ligands with hPRs 
and their transcriptional activity is also a function of phos-
phorylation of C-terminal amino acid residues as well as 
corresponding conformational changes in hPRs.39–41 Due to 
the limitations of this in silico molecular modeling study, we 
did not consider different conformational changes of hPRs 
due to their differential phosphorylation inside the cells, and 
further crystallographic studies are required to confirm our 
findings. Our results may contribute an insight into the risk 
of breast cancer due to nonendogenous ligands, especially 
estrogens that bind with hPRs, although the higher binding 
energy of cholesterol with hPR AB cannot be explained by 
this study. However, it can be predicted that, in the presence 
of a deficiency of progesterone or an abundance of choles-
terol, formation of a cholesterol-hPR AB complex may be 
favored at equilibrium, and may be another risk factor for 
breast cancer. This observation is in agreement with earlier 
studies reporting that increased total cholesterol levels are 
associated with development of breast cancer which is resis-
tant to certain drugs, eg, tamoxifen.42–44
Conclusion
The absence of higher binding affinity of hPRs with 
progesterone in comparison with estradiol and estrone in a 
cellular or animal model can be explained by ligand receptor 
interaction kinetics and also by study of the physiological fate 
of such ligands in animal and cellular systems. This study 
may enhance our understanding of the specificity in binding 
of steroid derivatives to hPR. Our findings advocate that 
estradiol and estrone binds with hPR A and hPR B monomers 
with higher affinity in comparison to progesterone. Such 
interactions cause aggressive tumor development. Hence, our 
study may be helpful in understanding why the hPR A:hPR B 
ratio and prolonged exposure of nonendogenous ligands, 
particularly estrogens, to hPRs in the presence and absence 
of progesterone, is a risk factor for breast cancer.
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